SUPERNUS PHARMACEUTICALS, INC. Other Noncash Income (Expense)
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Other Noncash Income (Expense) of -$578.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2026-06-30 was -$294.00K.
- SUPERNUS PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2026-03-31 was -$284.00K.
- SUPERNUS PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2025-12-31 was $5.72M, a 35.73% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2025-09-30 was -$6.52M.
- SUPERNUS PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2025 was -$1.89M.
- SUPERNUS PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2024 was -$2.07M, a 442.08% decline from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2023 was $606.00K.
- SUPERNUS PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2022 was -$1.20M, a 184.23% decline from fiscal 2021.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month | Other Noncash Income (Expense) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$294.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$578.00K 10-Q · filed 2026-08-03 | $5.14M derived: sum of 3 quarters · filed 2026-08-03 | -$1.37M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | -$284.00K 10-Q · filed 2026-05-05 | $5.44M derived: sum of 2 quarters · filed 2026-05-05 | -$1.08M derived: sum of 3 quarters · filed 2026-05-05 | -$1.69M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | $5.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$796.00K derived: sum of 2 quarters · filed 2026-03-02 | -$1.41M derived: sum of 3 quarters · filed 2026-08-03 | -$1.89M 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | -$6.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$7.13M derived: sum of 2 quarters · filed 2026-08-03 | -$7.61M 10-Q · filed 2025-11-06 | -$3.39M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | -$613.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$1.09M 10-Q · filed 2026-08-03 | -$3.78M 10-Q · filed 2025-08-05 | $3.13M derived: sum of 3 quarters · filed 2026-08-03 | $1.44M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-03-31 | -$476.00K 10-Q · filed 2026-05-05 | -$1.83M 10-Q · filed 2025-05-06 | $3.74M derived: sum of 2 quarters · filed 2026-05-05 | $2.05M derived: sum of 3 quarters · filed 2026-05-05 | -$830.00K derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.53M derived: sum of 2 quarters · filed 2026-03-02 | -$354.00K derived: sum of 3 quarters · filed 2026-03-02 | -$2.07M 10-K · filed 2026-03-02 | -$7.53M 10-K · filed 2025-02-25 | |||
| 2024-09-30 | -$1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.57M derived: sum of 2 quarters · filed 2025-11-06 | -$6.29M 10-Q · filed 2025-11-06 | -$8.28M 10-Q · filed 2024-11-04 | $4.80M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | -$2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$4.60M 10-Q · filed 2025-08-05 | -$6.62M 10-Q · filed 2024-08-06 | $6.49M derived: sum of 3 quarters · filed 2026-03-02 | $4.43M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | -$1.72M 10-Q · filed 2025-05-06 | -$2.45M 10-Q · filed 2024-05-08 | $9.37M derived: sum of 2 quarters · filed 2026-03-02 | $7.31M derived: sum of 3 quarters · filed 2026-03-02 | $1.35M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | $11.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.03M derived: sum of 2 quarters · filed 2026-03-02 | $3.06M derived: sum of 3 quarters · filed 2026-03-02 | $606.00K 10-K · filed 2026-03-02 | -$5.90M 10-K · filed 2025-02-25 | |||
| 2023-09-30 | -$2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$8.03M derived: sum of 2 quarters · filed 2024-11-04 | -$10.48M 10-Q · filed 2024-11-04 | -$3.70M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | -$5.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$8.43M 10-Q · filed 2024-08-06 | -$1.64M derived: sum of 3 quarters · filed 2025-02-25 | -$10.81M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | -$2.46M 10-Q · filed 2024-05-08 | $4.33M derived: sum of 2 quarters · filed 2025-02-25 | -$4.84M derived: sum of 3 quarters · filed 2025-02-25 | -$3.57M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $6.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$2.38M derived: sum of 2 quarters · filed 2025-02-25 | -$1.11M derived: sum of 3 quarters · filed 2025-02-25 | -$1.20M 10-K · filed 2025-02-25 | -$11.64M 10-K · filed 2023-03-09 | |||
| 2022-09-30 | -$9.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$7.90M derived: sum of 2 quarters · filed 2023-11-08 | -$7.98M 10-Q · filed 2023-11-08 | -$6.58M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.19M 10-Q · filed 2023-08-08 | $2.58M derived: sum of 3 quarters · filed 2023-08-08 | $1.96M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | -$84.00K 10-Q · filed 2023-05-09 | $1.31M derived: sum of 2 quarters · filed 2023-05-09 | $685.00K derived: sum of 3 quarters · filed 2023-05-09 | $134.00K derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $769.00K derived: sum of 2 quarters · filed 2023-03-09 | $218.00K derived: sum of 3 quarters · filed 2023-03-09 | $1.42M 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | -$629.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$1.18M derived: sum of 2 quarters · filed 2022-11-09 | $22.00K 10-Q · filed 2022-11-09 | -$638.00K derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2021-06-30 | -$551.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $651.00K 10-Q · filed 2022-08-08 | -$9.00K derived: sum of 3 quarters · filed 2023-03-09 | -$444.00K derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2021-03-31 | $1.20M 10-Q · filed 2022-05-12 | $542.00K derived: sum of 2 quarters · filed 2023-03-09 | $107.00K derived: sum of 3 quarters · filed 2023-03-09 | $538.00K derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2020-12-31 | -$660.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$1.09M derived: sum of 2 quarters · filed 2023-03-09 | -$664.00K derived: sum of 3 quarters · filed 2023-03-09 | -$1.45M 10-K · filed 2023-03-09 | ||||
| 2020-09-30 | -$435.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$4.00K derived: sum of 2 quarters · filed 2021-11-05 | -$794.00K 10-Q · filed 2021-11-05 | |||||
| 2020-06-30 | $431.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$359.00K 10-Q · filed 2021-08-06 | ||||||
| 2020-03-31 | -$790.00K 10-Q · filed 2021-05-07 | |||||||
| 2019-12-31 | -$2.23M 10-K · filed 2022-04-13 | |||||||
| 2018-12-31 | $1.64M 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |